Development of inhibitors of P. falciparum cGMP dependent protein kinase (PfPKG) for malaria chemoprevention
开发用于疟疾化学预防的恶性疟原虫 cGMP 依赖性蛋白激酶 (PfPKG) 抑制剂
基本信息
- 批准号:9751740
- 负责人:
- 金额:$ 69.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAllelesAnimalsAntimalarialsAppearanceBackBinding ProteinsBiological AssayBiologyBloodCellsCellular AssayChemicalsChemopreventionChemoprotectionChemoprotective AgentCyclic GMP-Dependent Protein KinasesDataDevelopmentDiseaseDrug TargetingEnsureEnzymatic BiochemistryEnzymesErythrocytesEvaluationFutureGenesGeneticGoalsGrowthHepG2HepatocyteHomologous GeneHumanImidazoleImmune responseIn VitroIncidenceInfectionInfection preventionInvadedIsoxazolesLeadLiverLuciferasesMalariaMeasuresMetabolicModelingMonitorMusOralOrganic ChemistryParasitemiaParasitesPathologyPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhosphotransferasesPlasma ProteinsPlasmodiumPlasmodium falciparumPlasmodium vivaxPreventionPricePropertyPyrrolesRecombinantsRelapseResistanceRodent ModelSeriesSeveritiesSpecificitySporozoitesStructureStructure-Activity RelationshipTechniquesTestingTimeToxic effectTransgenic Organismsanalogappropriate doseasexualbasecytotoxicity testdesignefficacy testingin vivoin vivo evaluationin vivo imaging systeminhibitor/antagonistkinase inhibitorliver infectionmouse modelnew therapeutic targetnovelnovel therapeuticspreventscaffoldscreeningside effecttissue/cell culturewater solubility
项目摘要
ABSTRACT
Malaria is caused by the protozoan parasite, Plasmodium. It begins with the infection by Plasmodium
sporozoites of the liver. This step is essential for the expansion of parasite numbers and the subsequent
symptomatic erythrocytic cycle. Inhibition of pre-erythrocytic infection will prevent malaria pathology and
relapses from P. vivax. Current drugs against pre-erythrocytic stages have significant side-effects or are
expensive. Therefore, there is an urgent need for new drugs against pre-erythrocytic stages of Plasmodium.
Our scientific premise is that inhibition of P. falciparum cGMP-dependent protein kinase (PfPKG) will block the
pre-erythrocytic cycle, and impede the erythrocytic cycle. Our hypothesis is based on data demonstrating that
(i) chemical inhibition of PfPKG prevents infection by P. falciparum sporozoites of tissue culture cells, and by P.
berghei sporozoites of mice. (ii) Chemical or genetic inhibition of P. berghei PKG blocks development of
invaded sporozoites into mature, infectious liver stages.
We propose to initiate a medicinal chemistry effort to synthesize and test a new chemical series of PfPKG
inhibitors. Validated hits from this series demonstrate in vitro selectivity for PfPKG, over its human homolog, in
enzymatic activity assays and are activite against the parasite. We propose a medicinal chemistry effort to
optimize molecules from this series to yield potent and PfPKG-selective compounds with whole-cell activity,
acceptable pharmaceutical properties for in vivo testing in mice.
摘要
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Plasmodium falciparum cGMP-Dependent Protein Kinase - A Novel Chemotherapeutic Target.
- DOI:10.3389/fmicb.2020.610408
- 发表时间:2020
- 期刊:
- 影响因子:5.2
- 作者:Rotella D;Siekierka J;Bhanot P
- 通讯作者:Bhanot P
Characterization of Competitive Inhibitors of Plasmodium falciparum cGMP-Dependent Protein Kinase.
- DOI:10.1002/cbic.202100704
- 发表时间:2022-04-05
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Discovery of Imidazole-Based Inhibitors of Plasmodium falciparum cGMP-Dependent Protein Kinase.
发现基于咪唑的恶性疟原虫 cGMP 依赖性蛋白激酶抑制剂。
- DOI:10.1021/acsmedchemlett.1c00540
- 发表时间:2021
- 期刊:
- 影响因子:4.2
- 作者:Bheemanaboina,RammohanRYadav;deSouza,MarianaLaureano;Gonzalez,MarianaLozano;Mahmood,ShamsUl;Eck,Tyler;Kreiss,Tamara;Aylor,SamanthaO;Roth,Alison;Lee,Patricia;Pybus,BrandonS;Colussi,DennisJ;Childers,WayneE;Gordon,John;Sie
- 通讯作者:Sie
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Purnima Bhanot其他文献
Purnima Bhanot的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Purnima Bhanot', 18)}}的其他基金
Development of inhibitors of P. falciparum cGMP dependent protein kinase (PfPKG) for malaria chemoprevention
开发用于疟疾化学预防的恶性疟原虫 cGMP 依赖性蛋白激酶 (PfPKG) 抑制剂
- 批准号:
9386266 - 财政年份:2017
- 资助金额:
$ 69.47万 - 项目类别:
Identification of the target of a compound that inhibits plasmodium sporozoites
抑制疟原虫子孢子的化合物靶标的鉴定
- 批准号:
8384110 - 财政年份:2012
- 资助金额:
$ 69.47万 - 项目类别:
Identification of the target of a compound that inhibits plasmodium sporozoites
抑制疟原虫子孢子的化合物靶标的鉴定
- 批准号:
8716838 - 财政年份:2012
- 资助金额:
$ 69.47万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 69.47万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 69.47万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 69.47万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 69.47万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 69.47万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 69.47万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 69.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 69.47万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 69.47万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 69.47万 - 项目类别: